BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ALN-CFB readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ALN-CFB\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07187401-11297@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20291129
DTEND;VALUE=DATE:20291130
SUMMARY:ALN-CFB: Phase 1/2 readout est. (NCT07187401)
DESCRIPTION:ALN-CFB\, phase 1/2\, Paroxysmal Nocturnal Hemoglobinuria.\nStu
 dy: A First-in-Human Safety and Efficacy Study of ALN-CFB\, a Small Interf
 ering RNA (siRNA) Targeting Complement Factor B\, in Adult Participants Wi
 th Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhi
 bitor\nEstimated primary completion: 29 November 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/aln-cfb#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07187401
URL:https://assetmemo.bio/drug/aln-cfb#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
